Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis.

Development of immunoprotection against visceral leishmaniasis (VL) focused on the identification of antigens capable of inducing a Th1 immune response. Alternatively, antigens targeting the CD8 and T-regulatory responses are also relevant in VL pathogenesis and worthy of being included in a preventive human vaccine. We assessed in active and cured patients and VL asymptomatic subjects the clinical signs and cytokine responses to the nucleoside hydrolase NH36 antigen and its N-(F1), central (F2) and C-terminal (F3) domains. As markers of VL resistance, the F2 induced the highest levels of IFN-γ, IL-1β, and TNF-α and, together with F1, the strongest secretion of IL-17, IL-6, and IL-10 in DTH and cured subjects. F2 also promoted the highest frequencies of CD3CD4IL-2TNF-αIFN-γ, CD3CD4IL-2TNF-αIFN-γ, CD3CD4IL-2TNF-αIFN-γ, and CD3CD4IL-2TNF-αIFN-γ T cells in cured and asymptomatic subjects. Consistent with this, the IFN-γ increase was correlated with decreased spleen ( = -0.428,  = 0.05) and liver sizes ( = -0.428,  = 0.05) and with increased hematocrit counts ( = 0.532,  = 0.015) in response to F1 domain, and with increased hematocrit ( = 0.512, 0.02) and hemoglobin counts ( = 0.434,  = 0.05) in response to F2. Additionally, IL-17 increases were associated with decreased spleen and liver sizes in response to F1 ( = -0.595,  = 0.005) and F2 ( = -0.462,  = 0.04). Conversely, F1 and F3 increased the CD3CD8IL-2TNF-αIFN-γ, CD3CD8IL-2TNF-αIFN-γ, and CD3CD8IL-2TNF-αIFN-γ T cell frequencies of VL patients correlated with increased spleen and liver sizes and decreased hemoglobin and hematocrit values. Therefore, cure and acquired resistance to VL correlate with the CD4-Th1 and Th-17 T-cell responses to F2 and F1 domains. Clinical VL outcomes, by contrast, correlate with CD8 T-cell responses against F3 and F1, potentially involved in control of the early infection. The -predicted NH36 epitopes are conserved and bind to many HL-DR and HLA and B allotypes. No human vaccine against is available thus far. In this investigation, we identified the NH36 domains and epitopes that induce CD4 and CD8 T cell responses, which could be used to potentiate a human universal T-epitope vaccine against leishmaniasis.